Company intelligence / Profile preview
Sichuan Prite Pharmaceutical
Sichuan, Chinascpurity.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sichuan Prite Pharmaceutical develops both small molecule drugs and gene therapies. Its most advanced product is dexmedetomidine hydrochloride for sedation, which has achieved approval status. Other pipeline assets include an investigational ketamine enantiomer for depressive disorders at Phase 1, a mucous secretion modulator at IND stage, and a discovery-stage respiratory disease program targeting CD51. The company has conducted multiple clinical trials with several programs progressing through early to mid-stage development.
- Therapeutic areas
- PulmonologyPsychiatryNeurology
- Modalities
- Small moleculeGene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Sichuan Prite Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Prite Pharmaceutical.